Clinical Trial

Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis

Study acronym: SAGE-PsA
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2023 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis (PsA). The investigators hope to discover biological and socio-cultural mechanisms that explain the differences in treatment response between men and women with PsA. The study investigators plan to recruit patients from approximately 30 sites across the world. Men and women with active PsA will be assessed before and after they start advanced therapies and information will be collected about sex- and gender-related factors through questionnaires and physical examination. Physicians will assess the patient response to treatment. The investigators will compare the response to treatment in men and women and assess what biological and socio-cultural factors contribute to differences in treatment response.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-07-12.
Trial Details
NCT Number NCT05954364
Lead Sponsor Women's College Hospital
Conditions Psoriatic Arthritis
Enrollment 540 participants
Start Date 2023-01-23
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-07-24